Emono

Neuralgia

Air Liquide Santé InternationalPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

53 Active assets in the Neuralgia cohort.

Asset / Sponsor	Phase	Rating
Pregabalin Ziauddin University	Phase 4	A
Capsaicin NeurogesX	Phase 3	BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Ataturk University	Phase 4	BBB
Bxcl501 Universidad Juárez Autónoma de Tabasco	Phase 4	BBB
MIDAZOLAM Minia University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Emono is also rated in:

Sickle Cell CrisisDormant

B

Indicative ·

60 / 100

major depressive disorderDormant

D

Indicative ·

30 / 100

major depressive disorderDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.